Tasyurek, H. M. Et Al. 2018. HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes. GENE THERAPY , vol.25, no.4 , 269-283.

Tasyurek, H. M., Eksi, Y. E., ŞANLIOĞLU, A. D., Altunbas, H. A., BALCI, M. K., Griffith, T. S., ... ŞANLIOĞLU, S.(2018). HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes. GENE THERAPY , vol.25, no.4, 269-283.

Tasyurek, Hale Et Al. "HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes," GENE THERAPY , vol.25, no.4, 269-283, 2018

Tasyurek, Hale M. Et Al. "HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes." GENE THERAPY , vol.25, no.4, pp.269-283, 2018

Tasyurek, H. M. Et Al. (2018) . "HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes." GENE THERAPY , vol.25, no.4, pp.269-283.

@article{article, author={Hale M. Tasyurek Et Al. }, title={HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes}, journal={GENE THERAPY}, year=2018, pages={269-283} }